US Drug Recall Register
Class II · Moderate risk Completed Initiated Mar 1, 2019 (8 years ago)

Drospirenone and Ethinyl Estradiol Tablets

Class II — Moderate risk. May cause temporary or reversible harm; serious harm unlikely.

Why it was recalled

Contraceptive Tablets Out of Sequence: Missing or incorrect tablet placement.

What was recalled

Drospirenone and Ethinyl Estradiol Tablets, USP, 3 mg/0.03 mg, 28 Tablets Blister, 1 Unit (NDC 60505-4183-1) packaged as 84 Tablets Blister, 3x1 Unit per carton (NDC 60505-4183-3), Rx Only, Manufactured for: Apotex Corp., Weston, FL 33326; Manufactured by: Oman Pharmaceutical Products Co. L.L.C., P.O. Box 1885, Postal Code 111, Seeb.

Recalling firm
Apotex Inc.
NDC code
60505-4183-1
Origin
N/A, Canada
Initiated by
Voluntary: Firm initiated
FDA recall number
D-0992-2019

What should you do? A recall doesn't always mean your specific bottle is affected - it often applies to certain lots only. Check the lot number on your package against the FDA notice, and talk to your pharmacist before stopping any medication.

Other Estradiol recalls

See all
Class II · Moderate risk Ongoing

Alyacen 7/7/7

Reason Failed Impurities/Degradation Specifications: This recall is being initiated due to out-of-specification results total impurities.

Glenmark Pharmaceuticals Inc., USA NDC 68462-556-29 D-0588-2026
Class II · Moderate risk Ongoing

Estradiol Gel

Reason Defective Container; packets were found to be either empty or partially full.

ANI Pharmaceuticals, Inc. NDC 70954-531-20 D-0543-2026
Class II · Moderate risk Ongoing

Estradiol

Reason Presence of Foreign substance - potential presence of metal particulate matter

F.H. INVESTMENTS, Inc. (dba Asteria Health) D-0315-2026
Class II · Moderate risk Ongoing

Estradiol

Reason Presence of Foreign substance - potential presence of metal particulate matter

F.H. INVESTMENTS, Inc. (dba Asteria Health) D-0314-2026
Class II · Moderate risk Ongoing

Estradiol

Reason Presence of Foreign substance - potential presence of metal particulate matter

F.H. INVESTMENTS, Inc. (dba Asteria Health) D-0313-2026